Blunted erythropoietin response to anemia in patients with Type 1 diabetes

Cotroneo, P; Ricerca, Bianca Maria; Todaro, L; Pitocco, Dario; Manto, Andrea; Ruotolo, Valeria; Storti, Sergio; Damiani, Patrizia; Caputo, Salvatore; Ghirlanda, Giovanni

doi:10.1002/1520-7560(200005/06)16:3<172::aid-dmrr117>3.0.co;2-d

Cited by 39 publications

(18 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anaemia in diabetes may be associated with blunted erythropoietin response 32 33. Erythropoietin has been shown to have neuroprotective effects in animal models,34 35 offering another possible explanation for the association between DPN and anaemia.…”

Section: Discussionmentioning

confidence: 99%

Predictors of vibration perception threshold in type 2 diabetic patients with proliferative retinopathy

Magri

Calleja

Buhagiar

et al. 2011

Postgraduate Medical Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Predictors of vibration perception threshold in type 2 diabetic patients with proliferative retinopathy

Magri

Calleja

Buhagiar

et al. 2011

Postgraduate Medical Journal

View full text Add to dashboard Cite

show abstract

“…Several studies have suggested that anemia occurs earlier in the course of diabetic nephropathy than in other forms of kidney disease, and anemia has been described among patients with mild to moderate chronic kidney disease (e.g., GFR 30–59 ml/min/1.73 m 2 ) as well as among those with more severe kidney disease [4]. Hypotheses to explain a higher rate of anemia among people with diabetes include damage to renal architecture produced by chronic hyperglycemia and consequent formation of advanced glycation end products [5]; autonomic neuropathy with decreased splanchnic sympathetic stimulation of erythropoietin production [6]; a blunted erythropoietin response to anemia among erythropoietin-producing cells [7]; and systemic inflammation [8]. Prior population-based studies in the United States have shown that chronic kidney disease-associated anemia is more prevalent among blacks than whites [9].…”

Section: Introductionmentioning

confidence: 99%

Ethnic differences in anemia among patients with diabetes mellitus: The Diabetes Study of Northern California (DISTANCE)

Ahmed

Warton

et al. 2009

American J Hematol

View full text Add to dashboard Cite

To examine ethnic differences in hemoglobin testing practices and to test the hypothesis that ethnicity is an independent predictor of anemia among patients with diabetes mellitus. We conducted a panel study to assess the rate of hemoglobin testing during 1999-2001 and the period prevalence and incidence of anemia among 79,985 adults with diabetes mellitus receiving care within Kaiser Permanente of Northern California. Anemia was defined as hemoglobin <13.0 g/dL in men or < 12.0 g/dL in women. Overall, 82.1% of the cohort was tested for anemia at least once during the 3-year study period. Mixed ethnicity patients were most likely to be tested, followed by whites, blacks, Latinos, and Asians (P < 0.0001). Fifteen percent of the cohort had prevalent anemia at baseline, and an additional 22% of those tested developed anemia during the study period. Anemia was more prevalent among blacks and mixed ethnicity persons compared with other racial/ethnic groups. Anemia was also more prevalent among those ≥70 years of age or with estimated glomerular filtration rate <60 ml/min/1.73 m 2 . In multivariable models, blacks had higher and Asians had lower odds of prevalent anemia and hazard ratios of incident anemia compared with whites. Within a large, diverse cohort with diabetes, ethnicity was predictive of anemia, even after adjustment for age, level of kidney function, and other potential confounders. Blacks with diabetes are at increased risk of anemia relative to whites. These differences may account for some of the observed ethnic disparities in diabetes complications. Am. J. Hematol. 85:57-61, 2010. V

show abstract

“…Serum EPO levels were decreased in type 1 diabetic patients with postural hypotension in comparison to age- and duration-matched type 1 diabetics free of complications as well as non-anemic, non-diabetic controls and patients with iron deficiency anemia (Winkler et al, 1999). A blunted EPO response to severe anemia has also been described as a result of autonomic neuropathy in studies of patients with both types 1 and 2 diabetes (Ricerca et al, 1999; Cotroneo et al, 2000; Spallone et al, 2004; Saito et al, 2007). …”

Section: Discussionmentioning

confidence: 91%

Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2Akita) diabetic mouse sympathetic ganglia

Schmidt¹,

Feng²,

Wang³

et al. 2011

Experimental Neurology

View full text Add to dashboard Cite

The Akita mouse is a robust model of diabetic autonomic neuropathy which develops severe diabetes following beta cell death, which occurs reproducibly at 3-4 weeks of age, and maintains the diabetic state without therapy for as long as 11 additional months. Neuritic dystrophy and neuronopathy involving prevertebral sympathetic superior mesenteric and celiac ganglia begin to develop within the first two months of onset of diabetes and are progressive with time. We have examined the effect of insulin implants resulting in normoglycemia and injections of ARA290, a small erythropoietin peptide which has no effect on glycemic parameters, on the reversal of established neuritic dystrophy and neuronopathy. We have found that 4 weeks of insulin therapy beginning at 2 months of diabetes resulted in normalization of blood glucose, body weight and HbA1c. Insulin therapy successfully reversed established neuritic dystrophy and neuronopathy to control levels. Numbers of sympathetic neurons were not significantly changed in either 3 month diabetic or insulin treated Akita mice. Treatment with ARA290 for 7 weeks beginning at 4 months of diabetes did not result in altered metabolic severity of diabetes as measured by blood glucose, body weight or HbA1c levels. ARA290 treatment was able to decrease neuritic dystrophy by 55-74% compared to untreated diabetics or in comparison to a separate group of diabetic animals representing the 4 month treatment onset point. Surprisingly, there was no effect of ARA290 on ganglionic neuron number or ongoing neuronopathy (pale/degenerating neurons) in diabetic Akita mice during this time period. The development of neuroprotective EPO-like peptides may provide a possible future therapy for this debilitating complication of diabetes; however, it appears that discrete elements may be differentially targeted by the diabetic state and may require selective therapy.

show abstract

Blunted erythropoietin response to anemia in patients with Type 1 diabetes

Cited by 39 publications

References 22 publications

Predictors of vibration perception threshold in type 2 diabetic patients with proliferative retinopathy

Predictors of vibration perception threshold in type 2 diabetic patients with proliferative retinopathy

Ethnic differences in anemia among patients with diabetes mellitus: The Diabetes Study of Northern California (DISTANCE)

Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2Akita) diabetic mouse sympathetic ganglia

Contact Info

Product

Resources

About